Tovecimig Slashes Disease Progression Risk by 56% in Phase 2/3 Biliary Tract Cancer Study
summarizeSummary
Compass Therapeutics announced highly positive topline secondary endpoint data from its COMPANION-002 Phase 2/3 study for tovecimig in patients with biliary tract cancer. The drug demonstrated a statistically significant improvement in Progression-Free Survival (PFS), reducing the risk of disease progression by 56% (HR=0.44, p<0.0001) and extending median PFS to 4.7 months compared to 2.6 months for paclitaxel alone. This significant de-risking event for CMPX follows the company's prior announcement of a webcast to present this data and is simultaneous with an 8-K filing. While the Overall Survival (OS) endpoint was not met due to high patient crossover from the control arm, the strong PFS benefit indicates a clinically meaningful impact in a patient population with high unmet medical need. The company plans to present the full dataset at an upcoming medical conference and will engage with the FDA to discuss potential regulatory pathways.
At the time of this announcement, CMPX was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $905.8M. The 52-week trading range was $1.67 to $6.88. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.